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Purpose: The objective of this study was to comparatively assess the bone regenerative ca-
pacity of absorbable collagen sponge (ACS), biphasic calcium phosphate block (BCP) and 
collagenated biphasic calcium phosphate (CBCP) loaded with a low dose of recombinant 
human bone morphogenetic protein-2 (rhBMP-2).
Methods: The CBCP was characterized by X-ray diffraction and scanning electron micros-
copy. In rabbit calvaria, four circular 8-mm-diameter defects were created and assigned to 
one of four groups: (1) blood-filled group (control), (2) rhBMP-2-soaked absorbable colla-
gen sponge (0.05 mg/mL, 0.1 mL; CS group), (3) rhBMP-2-loaded BCP (BCP group), or (4) 
rhBMP-2-loaded CBCP (CBCP group). The animals were sacrificed either 2 weeks or 8 weeks 
postoperatively. Histological and histomorphometric analyses were performed.
Results: The CBCP showed web-like collagen fibrils on and between particles. Greater di-
mensional stability was observed in the BCP and CBCP groups than in the control and the 
CS groups at 2 and 8 weeks. The new bone formation was significantly greater in the BCP 
and CBCP groups than in the control and CS groups at 2 weeks, but did not significantly 
differ among the four groups at 8 week. The CBCP group exhibited more new bone forma-
tion in the intergranular space and in the center of the defect compared to the BCP group 
at 2 weeks, but a similar histologic appearance was observed in both groups at 8 weeks.
Conclusions: The dose of rhBMP-2 in the present study enhanced bone regeneration in the 
early healing period when loaded on BCP and CBCP in rabbit calvarial defects.
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INTRODUCTION
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a highly effective tool 
in bone engineering in the field of dentistry [1-7]. The United States Food and Drug Admin-
istration (FDA) has approved the use of rhBMP-2 for dental use in extraction sockets and the 
maxillary sinus. Clinical trials for those indications have demonstrated the safety and effec-
tiveness of rhBMP-2 in these applications [8,9]. In addition, the off-label use of rhBMP-2 
was reportedly effective for overcoming severely defective situations [6,7].
There have been false and exaggerated reports regarding the safety of rhBMP-2 in spinal 
fusion surgery [10]. Compared to industry-sponsored publications, much higher complica-
tions were found for the same study population in FDA documents. Although clinical stud-
ies from the dental field have found no noteworthy complications [8,11], adverse effects 
associated with high doses of rhBMP-2, such as ineffective new bone formation, implant 
dislocation, and void formation, have been found in preclinical studies [12,13]. Thus, the 
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minimal dosages of rhBMP-2 needed for bone regeneration has 
been investigated [1,4,14-17].
The optimal delivery of rhBMP-2 requires the selection of an ap-
propriate carrier. The absorbable collagen sponge (ACS) was the 
first approved carrier, and its clinical efficacy has been demonstrat-
ed in human trials [9]. However, its structural durability was ques-
tioned in some situations [18,19]. Moreover, it was shown that the 
initial burst-release pattern obtained with ACS may lead to poten-
tial adverse effects [20] and may not be beneficial in sustaining 
bone-inducing activity [4].
Collagenated biphasic calcium phosphate (CBCP) has recently re-
ceived attention in the dental field [4,21]. As a bone substitute, CBCP 
shares the same basic characteristics of biphasic calcium phosphate 
(BCP), and exhibits comparable bone-regenerative potential [22,23]. 
As a carrier for rhBMP-2, the effectiveness of both BCP and CBCP 
has been demonstrated independently in several animal studies 
[3,4,21,24]. Both carriers were found to enhance new bone forma-
tion without hampering volume stability.
The addition of collagen to BCP may confer added benefits in 
bone regeneration. Collagen absorbs blood easily, and may create a 
favorable matrix for bone formation together with the network of 
BCP particles [25]. Previous studies have demonstrated that adding 
a collagen coating to a ceramic material enhances the proliferation 
rate, survival, and infiltration of osteoblasts [26,27]. In addition, 
ACS and BCP have different patterns of rhBMP-2 release, with BCP 
known to retain rhBMP-2 longer than ACS [28,29]; thus, the com-
bination of both materials may result in the sustained release of rh-
BMP-2 [4].
The proportions of slowly resorbing hydroxyapatite (HA) and rap-
idly resorbing beta-tricalcium phosphate (β-TCP) in BCP are known 
to affect regenerative outcomes, such as new bone formation, space 
maintenance, and material resorption [30]. The higher proportion of 
β-TCP in BCP is known to result in a greater amount of new bone 
formation, but it may impede volume stability due to the highly re-
sorptive characteristics of β-TCP [31]. The dependency of those be-
haviors on the HA:β-TCP ratio has also been simulated in CBCP [32]. 
It has been demonstrated that BCP with a higher ratio of β-TCP was 
more effective compared with a lower ratio of β-TCP when it was 
loaded with rhBMP-2 [1]. It is thus suspected that the strategy of 
loading rhBMP-2 onto CBCP containing a high ratio of β-TCP could 
be a way of enhancing the activity of rhBMP-2.
The objective of this study was to comparatively assess the bone 
regenerative capacity of three carriers loaded with a low dose of rh-
BMP-2: ACS, BCP, and CBCP, each containing a high ratio of β-TCP.
MATERIALS AND METHODS
Characterization of CBCP
The CBCP used in this study (Osteon II collagen, Genoss, Suwon, 
Korea) was composed of 94–96% BCP and 4–6% collagen (by vol-
ume). The BCP in the CBCP comprised 30% HA and 70% β-TCP, 
and the collagen was incorporated with BCP via a coating method. 
The CBCP was provided in cylindrical form, with dimensions of 8 
mm×2 mm (diameter×height).
For phase analysis of the CBCP, X-ray diffraction (XRD; RigakuUit-
ima III, Tokyo, Japan) with monochromatic Cu-Kα radiation at 40 kV 
and 200 mA was used; the XRD spectra were scanned at 2θ values 
in the range of 20°–60°. The microstructures of CBCP and BCP were 
observed using scanning electron microscopy (SEM; Tescan Vega II 
LSH, Warrendale, PA, USA).
Experimental animals
Ten male New Zealand white rabbits (14–16 weeks old, mean 
body weight 3.0–3.5 kg) were used for this study. The determina-
tion of the number of experimental animal followed our previous 
studies for evaluating bone regeneration in rabbit calvarial defects 
[31,33]. All procedures for animal selection, management, prepara-
tion, study design, surgical protocol, and postoperative care were 
approved by the Institutional Animal Care and Use Committee of 
Yonsei Medical Center (approval no. 2011-0031).
Study design
Four circular 8-mm-diameter defects were made in the calvarium 
of each rabbit and each of the four defects in each animal was as-
signed to one of the following four groups: (1) the defect was filled 
with blood coagulum (control), (2) the defect was filled with ACS 
soaked with rhBMP-2 (CS group), (3) the defect was filled with rh-
BMP-2-loaded BCP (BCP group), (4) the defect was filled with rh-
BMP-2-loaded CBCP (CBCP group). The ACS was manufactured in 
an 8 mm×2 mm (diameter×height) cylindrical shape (type I bovine 
collagen, Genoss, Suwon, Korea). 
The rhBMP-2 (Genoss, Suwon, Korea) was loaded onto each ma-
terial (i.e., ACS, BCP, and CBCP) at a concentration of 0.05 mg/mL 
in a volume of 0.1 mL (0.005 mg per defect), and with a binding 
time of 10 minutes. An independent person performed the random 
assignment of the defects to the experimental groups in the first 
experimental animal; in each subsequent animal the experimental 
grouping was assigned by rotating them in a clockwise manner.
Surgical procedures
The rabbits received an intramuscular injection of a mixture of 
ketamine hydrochloride (Ketalar, Yuhan, Seoul, Korea) and xylazine 
(Rompun, Bayer Korea, Seoul, Korea). The surgical site was shaved 
and disinfected using povidone iodine, and after local anesthesia 
with 2% lidocaine HCl (Huons, Seoul, Korea), an incision was made 
along the midsagittal line from the frontal area to the occipital 
area. A full-thickness flap was elevated using a periosteal elevator, 
and four circular defects with a diameter of 8 mm were created on 
the calvarium using a trephine bur under copious saline irrigation 
(Dentium, Seoul, Korea). Each defect was grafted with the assigned 
experimental material (Fig. 1). The flaps were then repositioned and 
sutured using synthetic monofilament suture material (4-0 Mono-
syn, B. Braun, Melsungen, Germany). The animals were sacrificed ei-
ther 2 weeks (n=5) or 8 weeks (n=5) postoperatively.
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Specimen preparation
En-bloc sections including the defects and surrounding tissues 
were harvested, rinsed with sterilized saline, and fixed in 10% buff-
ered formalin for 7 days. They were then decalcified in 5% formic 
acid for 14 days, gradually dehydrated in a series of ethanol solu-
tions, and then embedded in paraffin. Serial sectioning was per-
formed at a thickness of 5 μm, and the central-most section was 
selected, stained with hematoxylin and eosin, and analyzed.
Histomorphometric analysis
The specimens were examined using a light microscope (Leica DM 
LB, Leica Microsystems, Wetzlar, Germany), and histologic images 
were captured (CellSens Standard 1.11, Olympus, Center Valley, PA, 
USA) and saved. Histomorphometric analysis was performed with 
an image-processing system (Photoshop CS5, Adobe Systems, San 
Jose, CA, USA) by a single examiner (I.H.J.). The area of total aug-
mentation (TA; mm2), the defect closure rate (DC; %), the area of 
new bone (NB; mm2), and the area of residual material (RM; mm2) 
were measured.
Statistical analysis
Statistical analysis was performed using SPSS software (Version 
20.0, IBM Corporation, Armonk, NY, USA). The histomorphometric 
records of each group are presented as mean±standard deviation 
(SD) values. The small number of experimental animals required 
the use of nonparametric statistical analyses. To test the signifi-
cance of differences among groups for TA, DC, and NB at 2 and 8 
weeks, the Kruskal-Wallis test was used at a significance level of 
0.05 and then, the Wilcoxon rank sum tests with Bonferroni cor-
rection were used for post hoc pairwise comparisons at an adjust-
ed significance level of 0.00833 (0.05/6). The Wilcoxon rank sum 
tests were used for the comparison of RM between the BCP and 
Figure 1. Clinical photograph of the surgical procedure. The 8-mm-diameter 
defects were filled with blood coagulum (control), recombinant human bone 
morphogenetic protein (rhBMP-2)-loaded absorbable collagen sponge (CS), rh-
BMP-2-loaded biphasic calcium phosphate (BCP), or rhBMP-2-loaded colla-
genated BCP (CBCP).
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Figure 2. X-ray diffraction patterns of collagenated biphasic calcium phos-
phate (CBCP). The X-ray diffraction spectrum of the CBCP corresponded with 
the composite phases of hydroxyapatite and β-tricalcium phosphate.
Figure 3. Gross view and microstructure of biphasic calcium phosphate (BCP) and collagenated BCP (CBCP). (A) Clinical photographs in wet or dry conditions of 
BCP and CBCP. (B) Scanning electron microscopy views of BCP and CBCP.
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CBCP groups at 2 and 8 weeks, and for the comparison of all pa-
rameters between the 2 and 8 weeks with a level of 0.05 consid-
ered statistically significant. 
RESULTS
The phase analysis of the CBCP block is shown in Fig. 2; the 2θ 
values of the highest two intensity peaks were 31.8° and 31.0°. 
When they were compared with Joint Committee on Powder Dif-
fraction Standards card Nos. 09-0432 (HA) and 9-0169 (β-TCP), 
the XRD spectrum of the collagenated BCP corresponded with the 
composite phases of HA and β-TCP. As shown in gross view and 
microscopy, CBCP was able to hold easily in both dry and wet con-
ditions and revealed a web-like structure of collagen fibrils on the 
BCP particles (Fig. 3).
All of the experimental animals exhibited uneventful healing, 
Figure 4. Histologic observations at 2 weeks postsurgery. (A, B) the control group, (C, D) the collagen sponge (CS) group, (E, F) the biphasic calcium phosphate 
(BCP) group, (G, H) the collagenated BCP (CBCP) group. (B, D, G, F) Higher magnification views of the boxed area in A, C, E, and G, respectively. The black arrows 
indicate the margins of the defect. The black and yellow arrowheads indicate osteoblasts and osteoclasts, respectively. Hematoxylin-eosin stain; scale bar (A, C, 
E, G)=1 mm, (B, D, G, F)=200 μm. NB, newly formed bone; RM, residual material.
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and no inflammatory changes or allergic reactions were observed. 
However, the specimens from one animal assigned to the group 
that had 8 weeks of healing were not included in the microscopic 
analysis due to a technical error in the histologic processing. Thus, 
five and four samples were analyzed for the 2 and 8 weeks groups, 
respectively.
At 2 weeks, the defects in the control group were almost com-
pletely filled with soft tissues, and were depressed and flattened in 
shape. Minimal bone ingrowth was observed and only at the de-
fect margins. The gross morphology of the CS group was similar to 
that of the control group. Bone formation started mainly at the 
periphery of the defects, and residual collagen was observed with-
in them. A larger number of blood vessels was observed in the CS 
group than in the control group. In the BCP and CBCP groups the 
thickness of the original calvarial bone was mostly maintained 
with new bone, residual particles, and fibrovascular tissues. Bone 
Figure 5. Histologic observations at 8 weeks postsurgery. (A, B) the control group, (C, D) the collagen sponge (CS) group, (E, F) the biphasic calcium phosphate 
(BCP) group, (G, H) the collagenated BCP (CBCP) group. (B, D, G, F) Higher magnification views of the boxed area in A, C, E, and G, respectively. The black arrows 
indicate the margins of the defect. The black and yellow arrowheads indicate osteoblasts and osteoclasts, respectively. Hematoxylin-eosin stain; scale bar (A, C, 
E, G)=1 mm, (B, D, G, F)=200 μm. NB, newly formed bone; RM, residual material.
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formation was more prominent in the BCP and CBCP groups than 
in the CS and control groups. Generally, bone formation was more 
prominent in the intergranular space in the CBCP group compared 
to the BCP group. The CBCP group exhibited more active bone for-
mation above the dura mater than the BCP group, and this pattern 
was particularly distinct in the center of the defects. The number 
and size of blood vessels appeared to be greater in the CBCP group 
than in the BCP group (Fig. 4).
At 8 weeks, the control group and CS group still exhibited a de-
pressed morphology. Bone ingrowth from the periphery of the de-
fects had increased, and several bony islands could be observed. 
There was a larger number of bony islands in the CS group than in 
the control group. No remnants of collagen could be seen in the 
CS group. In the BCP and CBCP groups, the augmented space was 
well-maintained, and much of the space formerly filled with resid-
ual material and fibrovascular tissues at 2 weeks was replaced by 
new bone at 8 weeks. New bone formation was observed around 
the remnant material under the skin flaps in the BCP and CBCP 
groups. Most of the surface of residual particles was in contact 
with new bone. Several osteoblasts were observed near the rem-
nant material and the front of new bone. Many osteocytes and re-
versal lines were observed, along with some empty lacunae (Fig. 5).
The histomorphometric results are given in Table 1 and Fig. 6. TA 
and NB were significantly greater in the BCP and CBCP groups 
compared to the control and CS groups at 2 weeks (P=0.008 for 
all), but did not significantly differ among the four groups at 8 
weeks. DC was significantly greater in the BCP and CBCP group 
compared to the control group, and was not statistically significant 
Table 1. Histomorphometric results of total augmentation (TA), the defect clo-
sure rate (DC), the area of new bone (NB) and the area of residual material (RM) 
TA (mm2) DC (%) NB (mm2) RM (mm2)
2 weeks (n=5)
   Control 2.97±0.57 15.81±6.00 0.30±0.07 -
   CS 3.33±0.69 30.22±14.08 0.46±0.18 -
   BCP 15.08±1.33a,b) 65.59±24.56a) 1.72±0.41a,b) 5.21±1.02
   CBCP 15.59±1.79a,b) 66.81±29.48a) 2.46±1.25a,b) 5.23±1.22
8 weeks (n=4)
   Control 4.40±0.89 42.73±5.51c) 1.32±0.40c) -
   CS 6.77±4.03 66.76±28.80 2.23±1.23 -
   BCP 10.94±3.56 74.78±24.81 3.46±2.43 3.00±1.02c)
   CBCP 12.55±3.88 85.76±16.85 4.82±2.17 2.95±0.85c)
Values are presented as mean±standard deviation. 
CS, the group received rhBMP-2-soaked absorbable collagen sponge; BCP, the group 
received rhBMP-2-loaded biphasic calcium phosphate; CBCP, the group received rhBMP-
2-loaded collagenated biphasic calcium phosphate.
a)Significantly different compared to the control group (P<0.083, an adjusted significance 
level using Bonferroni correction).
b)Significantly different compared to the CS group (P<0.083, an adjusted significance level 
using Bonferroni correction).
c)Significantly different compared to the corresponding parameter at 2 weeks (P<0.05).
among the CS, the BCP, or the CBCP group at 2 weeks. At 8 weeks, 
a statistically significant difference in DC was not noted among the 
four groups. NB and DC increased significantly between 2 and 8 
weeks in the control group (P=0.014 for both) but not in the CS, 
BCP, or CBCP group. RM did not differ significantly between the 
BCP and CBCP groups at either healing time point, and decreased 
significantly between 2 and 8 weeks (P=0.014 for both).
DISCUSSION
Despite a great deal of research effort, the ideal treatment mo-
dality using rhBMP-2 for bony defects has yet to be established. 
When using a particular dose of rhBMP-2 the various carrier sys-
tems can be similarly effective, but the efficacy may vary widely 
when a lower dose of rhBMP-2 is used. Thus, determination of the 
optimal combination of carrier and rhBMP-2 is essential. In the 
present study it was found that BCP and CBCP loaded with a low 
dose of rhBMP-2 had greater bone-forming capacity than ACS in 
rabbit calvarial defects, and particularly at 2 weeks post-procedure.
Our previous studies on the optimal dose of rhBMP-2 involved 
the testing of several doses (ranging from 0.015 mg to 0.15 mg) in 
rabbit models [4,12,16-18]. In the rabbit sinus, a dose of 0.15 mg 
loaded on BCP led to inhomogeneous bone formation (confined to 
the area adjoining the sinus membrane) [12], and a dose of 0.015 
mg resulted in only an insignificant increase in new bone [17]. In 
the rabbit calvaria, the lower dose of 0.01 mg loaded on BCP sig-
nificantly enhanced bone formation [16]. In the present study, the 
dose of 0.005 mg (the lowest dose in the studies by our group) was 
loaded on ACS, BCP and CBCP. New bone was significantly greater 
in the BCP and CBCP groups than in the control and ACS groups at 
2 weeks, but insignificantly greater at 8 weeks. This indicates that 
the optimal dose of rhBMP-2 may vary depending on anatomical 
sites and carrier materials.
Regeneration with a high purity of target tissue requires a com-
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pletely resorbing scaffold, such as ACS, but tension or pressure at 
the recipient site may predetermine the limit or jeopardize the im-
mature regenerated tissue in specific situations [34]. Thus, the me-
chanical stability of the scaffold may also be a prerequisite, de-
pending on the characteristics of the recipient site. The BCP and 
the CBCP groups in the present study exhibited enhanced space-
maintaining stability compared to the CS group, which might be 
one of the contributing factors for greater bone regeneration. 
Consistent with the present study, Lu et al. demonstrated that the 
combination of collagen, β-TCP, and HA loaded with rhBMP-2 re-
sulted in significantly increased new bone in the supra-alveolar 
peri-implant defect model compared to the ACS carrier [19].
Compared to conventional BCP, CBCP may provide a more favor-
able environment for bone induction. Although new bone forma-
tion in the CBCP group was not significantly enhanced at 8 weeks 
in the present study, an altered bone-induction pattern could be 
detected in the histologic sections, especially at 2 weeks. Newly 
formed bone in the CBCP group was found more frequently in the 
intergranular spaces and in the center of the defect than it was in 
the BCP group, which indicates that the web-like collagen network 
in CBCP may have enhanced the proliferation and infiltration of 
osteoblasts [26,27] and vascular endothelial cells around [35,36] 
and lastly strengthened the effect of rhBMP-2. This finding was 
also demonstrated in the canine mandibular defect model [21], 
whereby CBCPs with different ratios of HA and β-TCP loaded with 
rhBMP-2 resulted in enhanced bone formation compared to non-
collagenated BCPs loaded with rhBMP-2.
The content of collagen in the CBCP in the present study was 
4–7% (by volume). Given that the addition of this small amount of 
collagen increased the mean area of new bone and favorably af-
fected the bone healing pattern, using a larger volume of collagen 
in CBCP may alter the effect of rhBMP-2. In a pilot study, Yun et al. 
[21] recently compared the CBCPs containing 4–7% and 47% col-
lagen (by volume). In that study, the CBCP with the lower collagen 
content resulted in more new bone formation than that with the 
higher collagen content; the volume stability of the latter may have 
been impaired due to collagen comprising almost half of its vol-
ume. From a clinical viewpoint, an increased collagen content may 
enhance the clinical manageability of the carrier due to the con-
comitant increase in tensile and shear strengths. Thus, determining 
the optimal balance between the regenerative capacity and clinical 
manageability of carriers, in terms of the ratio of collagen content, 
requires further study. 
Collagenated bone substitutes including CBCP in the present 
study have received attention for several indications, such as ridge 
preservation, lateral onlay grafting, periodontal regeneration, and 
sinus augmentation. They offer improved clinical manageability in 
unfavorable types of defect, preventing scattering of graft particles 
and providing moldability to fit the specific defect morphology. Bo-
vine HA incorporated with collagen matrix was found to be easily 
fixed to the lateral surface of the canine maxilla [2], and CBCP was 
shown to be useful for the vertical augmentation of rabbit calvaria 
[16]. When loaded with rhBMP-2, the three-dimensionally prefab-
ricated porous structure of these carriers provides a favorable envi-
ronment for new bone formation and angiogenesis [2,4].
The term “optimal” can be defined as “providing efficacy with a 
small dose” in regard to rhBMP-2 application. However, clinical 
situations and carrier materials should be taken into consideration 
for this optimization. Within the limitations of the present study, 
0.005 mg of rhBMP-2 could improve bone regeneration at an early 
healing period when loaded on BCP and CBCP in the rabbit calvar-
ium. Different healing patterns of CBCP, such as more new bone 
formation along the intergranular space at an early healing period 
may give additional benefits together with easy clinical manage-
ability. Future studies should be performed to confirm those find-
ings in a larger number of animals and in different models.
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